SAN FRANCISCO — A one-time in-office injection of a gene therapy helped improve disease severity in patients with diabetic retinopathy.
At Retina Subspecialty Day at the American Academy of Ophthalmology meeting, Mark R. Barakat, MD, said diabetic retinopathy is often left untreated due to a high treatment burden.
“The goal of a one-time in-office injection of gene therapy is to stabilize the disease severity, perhaps improve it and reduce the number of eyes that proceed to vision-threatening complications,” he said.
In the phase 2 ALTITUDE trial, patients with moderately